Cirtuvivint - Biosplice Therapeutics
Alternative Names: NSC-835563; SM-08502Latest Information Update: 16 Jul 2024
At a glance
- Originator Samumed
- Developer Biosplice Therapeutics
- Class Amides; Antineoplastics; Isoquinolines; Piperazines; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action DYRK kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Colorectal cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
- Preclinical Haematological malignancies
Most Recent Events
- 09 Jul 2024 National Cancer Institute plans a phase I trial for Acute myeloid leukaemia and Myelodysplastic syndromes (Monotherapy, Combination therapy) (PO) in September 2024 (NCT06484062)
- 31 May 2024 Pharmacodynamics data from a preclinical trial in Acute myeloid leukemia presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 14 Nov 2022 Biosplice Therapeutics terminates a phase I trials for Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA due to business reasons by Sponsor (PO, Tablet) (NCT03355066)